China’s drug industry pivots to AI-powered candidates to drive next wave of deals
After China’s cross-border deals for innovative drugs hit a record US$110 billion in the first half of 2026, the sector is now pivoting towards artificial intelligence-powered candidates to drive the next wave of transactions. China accounted for about 30 per cent of all new drug